Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 3, 2018updated 22 Nov 2018 11:23am

Pulmonx obtains approval for Zephyr Endobronchial Valves in US

Pulmonx, an interventional pulmonology treatments provider, has secured the US Food and Drug Administration (FDA) approval for its Zephyr Endobronchial Valve System to treat severe emphysema, a type of chronic obstructive pulmonary disease (COPD).

Pulmonx, an interventional pulmonology treatments provider, has secured the US Food and Drug Administration (FDA) approval for its Zephyr Endobronchial Valve System to treat severe emphysema, a type of chronic obstructive pulmonary disease (COPD).

Zephyr has been designed as a minimally invasive bronchial valve that can be implanted in the airways during a bronchoscopic procedure to occlude a diseased part of the lungs and minimise hyperinflation.

During inhalation, the valves close and prevent entry of air into the damaged part and during exhalation, the valves open to let out trapped air.

“The regulatory decision comes after a review of positive clinical data from the LIBERATE Study and two other multi-centre randomised control trials.”

This mechanism is said to aid the healthier parts of the lungs to expand, thereby lifting pressure off the diaphragm and in turn reducing shortness of breath.

FDA Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices division acting director Tina Kiang said: “Treatment options are limited for people with emphysema who have severe symptoms that have not improved from taking medicines.

“This novel device is a less invasive treatment that expands the options available to patients.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The regulatory decision comes after a review of positive clinical data from the LIBERATE Study and two other multi-centre randomised control trials.

Data from LIBERATE showed more patients treated with Zephyr Valves and medical management could breathe easier, were more active, experienced lesser shortness of breath and had a significant improvement in the quality of life when compared to those who received only medical management.

Some of the adverse events observed during the study were death, air leak or pneumothorax, worsening of emphysema, pneumonia, coughing up blood, chest pain and shortness of breath.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU